The estimated Net Worth of Gary M Pfeiffer is at least $16 million dollars as of 12 November 2018. Mr. Pfeiffer owns over 10,000 units of Quest Diagnostics stock worth over $8,287,480 and over the last 20 years he sold DGX stock worth over $7,373,186. In addition, he makes $323,044 as Independent Director at Quest Diagnostics.
Gary has made over 9 trades of the Quest Diagnostics stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of DGX stock worth $65,600 on 12 November 2018.
The largest trade he's ever made was selling 42,643 units of Quest Diagnostics stock on 15 November 2016 worth over $3,628,493. On average, Gary trades about 2,421 units every 40 days since 2004. As of 12 November 2018 he still owns at least 53,969 units of Quest Diagnostics stock.
You can see the complete history of Mr. Pfeiffer stock trades at the bottom of the page.
Gary M. Pfeiffer serves as Independent Director of the Company. Mr. Pfeiffer retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer is Lead Independent Director of Internap Corporation, and served as a director of TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non-executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016.
As the Independent Director of Quest Diagnostics, the total compensation of Gary Pfeiffer at Quest Diagnostics is $323,044. There are 11 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of $10,118,500.
Gary Pfeiffer is 70, he's been the Independent Director of Quest Diagnostics since 2004. There are 2 older and 19 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty et Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: